inflammatory disorder that predominantly affects the stomach and the small intestine. The disease is divided into three subtypes (mucosal, muscular and serosal) according to klein's classification, and its manifestations are protean, depending on the involved intestinal seg ments and layers. Hence, accurate diagnosis of EGE poses a significant challenge to clinicians, with evidence of the following three criteria required: Suspicious clinical symptoms, histologic evidence of eosinophilic infiltration in the bowel and exclusion of other pathologies with similar findings. In this review, we designed and applied an algorithm to clarify the steps to follow for diagnosis of EGE in clinical practice. The management of EGE represents another area of debate. Prednisone remains the mainstay of treatment; however the disease is recognized as a chronic disorder and one that most frequently follows a relapsing course that requires maintenance therapy. Since prolonged steroid treatment carries of risk of serious adverse effects, other options with better safety profiles have been proposed; these include budesonide, dietary restrictions and steroidsparing agents, such as leukotriene inhibitors, azathioprine, anti-histamines and mast-cell stabilizers. Single cases or small case series have been reported in the literature for all of these options, and we provide in this review a summary of these various therapeutic modalities, placing them within the context of our novel algorithm for EGE management according to disease severity upon presentation. Core tip: Eosinophilic gastroenteritis (EGE) is a hetero geneous inflammatory bowel disorder, which commonly follows a chronic and relapsing course. To date, only single cases or small case series provide insights into its diagnosis and management. This manuscript reviews the different diagnostic tools utilized in practice and provides an algorithm for diagnosis. It also provides a summary of 
INTRODUCTION
Eosinophilic gastroenteritis (EGE) is a rare inflammatory disorder characterized by eosinophilic infiltration of the intestinal wall. Since its first description, about 8 decades ago, reports of subsequent cases have rev ealed a widely variable and heterogeneous profile of physical manifestations. Studies from the United States have found a prevalence ranging between 8.4 and 28 per 100000 [1, 2] , with a slightly increasing incidence over the past 50 years [3] ; additionally, the disease is well known to be more common among the pediatric population, with afflicted adults typically between the 3 rd and 5 th decade of life [4] . Intriguingly, the more recent estimates of EGE in the United States have found a shift from male preponderance [4, 5] to female predominance [2] . Higher socioeconomic status, Caucasian race and excess weight may be risk factors of EGE [3] , and a possible hereditary component (genetic factor) is suggested by reports of familial cases [6] . Concomitant allergic disorders, including asthma, rhinitis, eczema and drug or food intolerances, are present in 45% to 63% of the reported EGE cases [1, 3] ; moreover, 64% of reported cases include a family history of atopic diseases [7] . Some studies have found an association with other autoimmune conditions, such as celiac disease [8] , ulcerative colitis [9] and systemic lupus erythematosus [10] . These data collectively suggest that EGE may result from immune dysregulation in response to an allergic reaction; yet, a triggering allergen is not always identified. Indeed, about 50% of EGE cases involving the alimentary tract have been detected by allergy testing to address a suspected food allergy [3] . Other environmental factors, such as parasitic infestation and drugs, may act as predisposing agents as well [11] .
Both immunoglobulin E (IgE) dependent and de layed TH2 cellmediated allergic mechanisms have been demonstrated to be involved in the pathogenesis of EGE. Interleukin 5 (IL5) has also been shown to play an essential role in the expansion of eosinophils and their recruitment to the gastrointestinal (GI) tract, the mechanism underlying the pathogenic hallmark of EGE. Chemokines, namely eotaxin 1 and α4b7 integrin, are also known to contribute to eosinophilic homing inside the intestinal wall. Other mediatorsmost notably IL3, IL4, IL13, leukotrienes and tumor necrosis factor (TNF)alphaact to enhance eosinophilic trafficking and have been proposed to help in prolonging lymphocytic and eosinophilic activity [1113] . Many of these immune related molecules are currently under consideration as potential targets for molecular therapy of EGE.
Once recruited to the GI tract, the activated eosi nophils induce a significant inflammatory response by secreting a variety of mediators including the cytotoxic granules that lead to structural damage in the infiltrated intestinal layers [12] . Thus, EGE can affect any GI segment, but reports have shown that the small intestine and stomach are the most predominant areas [4] . In clinical practice, the Klein classification system [14] is used to categorize the disease type according to the involved intestinal layer; the 3 Klein categories are mucosal, muscular and serosal. The mucosal layer is the most commonly affected, as has been reported in the ma jority of case series in the literature, with prevalence ranging between 57% in older estimates [4] and 88% to 100% in more recent estimates [3, 15] . Furthermore, the muscular and serosal types are commonly associated with concomitant mucosal eosinophilic infiltration, which raises the hypothesis of centrifugal disease progression from the deep mucosa toward the muscular and serosal layers [3] .
DIagNOsIs
Diagnosis of EGE requires three criteria, namely: (1) presence of GI symptoms; (2) histologic evidence of eosinophilic infiltration in one or more areas of the GI tract; and (3) exclusion of other causes of tissue eosinophilia [16] (Figure 1 ).
While EGE manifestations vary depending on the affected GI layer, abdominal pain is the predominant presenting symptom among all 3 of the disease types [5] . Involvement of the mucosal layer may cause diarrhea, vomiting, proteinlosing enteropathy and malabsorption, which in turn can manifest as anemia, hypoalbuminemia and weight loss. Involvement of the muscular layer can lead to a partial or total intestinal obstruction. Involvement of the serosal layer may cause peritoneal irritation, which can lead to ascites, peritonitis and perforation in more severe cases; intestinal intussusception may occur in the serosal type as well [17] . An additional manifestation of the disease, peripapillary duodenal disease, which is secondary to the eosinophilic infiltration of the peripapillary duodenal region, might result in pancreatitis and biliary obstruction [18, 19] . Some laboratory findings are sufficient to raise suspicion of EGE, although they are not adequate for an EGE diagnosis. About 70% of cases present with peripheral eosinophilia [4, 20] and EGE cases with deep serosal involvement frequently have higher absolute eosinophilic counts (AECs) [20] , the latter of which may also be associated with greater risk of relapse [20] . Elevated IgE is reportedly present in about twothirds of EGE cases [5] and a trend of increased erythrocyte sedimentation rate (ESR) values has been observed. Finally, some reports of EGE cases have demonstrated that peritoneal fluid analysis shows exudative fluid with a net eosinophilic predominance reaching about 90% of white blood cells (WBCs) [21] . Following assessment of the patient's initial pre sentation, the next step toward diagnosis will require either endoscopy or imaging studies (Figure 1 ). Endo scopic findings suggestive of EGE include normal aspect, erythematous friable mucosa, ulcers, pseudopolyps and polyps [22, 23] , none of which are sensitive or specific for diagnosis of the disease. Thus, findings from endoscopic biopsies can play an essential role in diagnosis, as evidenced by the reported detection rate of 80% for this examination modality [24] . Unfortunately, however, the patchy distribution profile of the disease necessitates multiple biopsies, at least 5 or 6, be obtained from both endoscopically abnormal and normal mucosa, as the latter may mask about 60% of histologically proven disease [15] . Even in cases of negative initial biopsies, but with an otherwise high suspicion index, repeat endoscopy may be useful. Endoscopic ultrasound is also a useful tool for assessing muscular and subserosal involvement, as it facilitates access to these tissues for biopsy via fine needle aspiration [25, 26] . Imaging studies are another diagnostic modality that has proven useful. In addition to guiding biopsy taking efforts, ultrasound can detect ascites and intestinal wall thickening [27] . Computed tomography (CT) scan can detect diffuse thickening of mucosal folds, intestinal wall thickening, ascites and obstruction. Two other Accordingly, we suggest dividing the disease into four classifications mild, moderate, severe and complicated based upon the initial clinical manifestations, initial laboratory findings, and severity of GI structural damage as assessed by radiologic, endoscopic and histologic examinations (Table 1) [3439]
. Following confirmation of eosinophilic infiltration to the GI tract, the exclusion of other possible causes of the initial clinical presentation is crucial for diagnosis of EGE ( Figure  1 ). These other possible causes include parasitic infections (i.e., Strongyloides, Ascaris, Ancylostoma, Anisakis, Capillaria, Toxicara, Trichiura and Trichinella spp), drugs, vasculitis (i.e., ChurgStrauss syndrome, polyarteritis nodosa), connective tissue diseases, inflammatory bowel diseases (IBDs), celiac disease, lymphoma, leukemia and mastocytosis. Furthermore, ruling out of the hyper eosinophilic syndrome is of special value as it is a myelo proliferative disorder, characterized by idiopathic high peripheral eosinophilic count of > 1500 eos/hpf persisting for > 6 mo and having severe systemic implications due to its multisystem involvement, including heart, central nervous system, skin, lungs, liver and kidneys in addition to the GI tract [34, 40] . It is also important to perform a food allergy evaluation in all patients with suspected EGE. Both IgE dependent (specific IgE and skin prick) and nonIgE TH2 dependent (skin patch) allergy tests may aid in identification of the specific allergen related to a case. However, these tests lack both sensitivity (missing about 40% of causative agents) and specificity (capable of overlapping detection of up to 14 allergens in some cases) [41] . A combination of both testing types, however, might enhance their overall predictive value for identifying the EGEprovoking scanographic signs that may appear secondary to bowel wall layering are the "Halo sign" and the "araneidlimb like sign", both of which can aid in differentiating between an inflammatory and a neoplastic lesion [28, 29] and in ruling out extraintestinal pathologies. The imaging modality of Tc99m hexamethylpropyleneamineoxime (HMPAO) labeled WBC scintigraphy provides a topographic description of the disease and allows for monitoring of therapeutic response [30] ; however, this technology is not widely available and is not yet established as a reliable diagnostic tool for EGE.
While many tools can aid in obtainment of biopsies, the preferred method is still surgery, which provides a full thickness specimen for comprehensive pathology and the most accurate diagnosis, particularly for the muscular and serosal disease types [31] . Histologic examination remains the cornerstone of diagnosis. An absolute eosinophil count of at least 20 eosinophils/hpf has been set in most reports [7, 23] as the threshold for fulfilling the second diagnostic criterion. The presence of intraepithelial eosinophils and eosinophils in the Peyer's patches [32] , as well as of extracellular deposition of eosinophil major basic proteins (MBPs) [33] , favor development of EGE. The latter finding, in particular, reflects the degree of degranulation in activated eosinophils, which is directly linked to greater structural damage [6] . Observation of villous atrophy, crypt hyperplasia or abscesses and epithelial degenerative/ regenerative changes are also common findings of EGE. As such, some researchers have emphasized the importance of a subjective histological analysis, in addition to the eosinophilic count, as an important aspect for diagnosis [34] . Non-significant 1 wk 1%-2% 1 mo 5% 3 mo 7.5% 6 mo 10% 1 wk > 2% 1 mo > 5% 3 mo > 7.5% 6 mo > 10% Laboratory Alb, g/dL > 3 2.5-3 < 2.5 HB, g/dL [36] 9.5-11 8-9.5 < 8 AEC, cells/µL [37] < 1500 1500-5000 > 5000 Radiologic Ascites None or mild Moderate volume Large volume Perforation Intestinal wall thickening [38] Mild (1-2 cm) Focal (< 10 cm) diagnosis was found to be an independent predictor of relapses, as was extensive intestinal involvement. Some case series have found higher relapsing rates of 60% to 80% [7, 26, 44] , while others have noted a possible association between younger age (under 20yearold) and disease recurrence [24] . Unfortunately, research has not identified any other predictors of EGE disease evolution. Thus, it is worth contemplating maintenance treatment for patients after the initial induction phase has passed (Figure 2) , taking into consideration the safety profile of the drug in use. It is important to remember, however, that the duration of such maintenance therapy cannot be predicted at this point.
TREaTMENT MODaLITIEs

Proton pump inhibitor and Helicobacter pylori eradication
Proton pump inhibitor (PPI) treatment has been shown to improve the extent of duodenal eosinophilic infiltration in a patient with EGE, and the mechanism has been hypothesized to involve blockade of IL4 and IL13 activity [45] . H. pylori eradication has also been postulated as capable of inducing a cure of EGE disease [46] . The antibiotic clarithromycin, which is commonly used to agents [42] .
MaNagEMENT
Although spontaneous remission reportedly occurs in around 30% to 40% of EGE cases [20, 43] , most patients require ongoing treatment. Many therapeutic options have been suggested, including dietary considerations, steroids, leukotrienes inhibitors and mast cells stabilizers. All of these treatment approaches have been described in small case series, but no randomized controlled or comparative trials have been published in the publicly available literature to describe the efficacies of different treatments or predictors of response to one or another option. Thus, no clear, systematic and practical strategy has been put forth for healthcare teams to follow in their management of EGE cases.
EGE is recognized as a chronic inflammatory disorder. Pineton de Chambrun et al [20] described three different longterm progression patterns: Nonrelapsing disease (42%), commonly seen in patients with the serosal type; relapsingremitting disease (37%), occurring primarily in patients with the muscular type; and chronic (persistent) disease (21%), predominantly observed in patients with the mucosal type. As mentioned above, a high AEC at 
Budesonide
Budesonide, a common steroid treatment of Crohn's disease and ulcerative colitis, has a high affinity for steroid receptors and produces fewer side effects due to its lower systemic impact. It has also been demonstrated as effective for induction and maintenance of remission in the majority of reported cases (Table 2 ) [15, 26, 5259] . The usual dose is 9 mg/d, which can be tapered to 6 mg/d for use as prolonged maintenance therapy. The better safety profile of budesonide, compared to other steroid drugs, is of particular benefit for management of EGE cases over the long term, especially in the setting of steroid dependent disease.
Azathioprine
Azathioprine, a common immunosuppressive agent used in organ transplant and patients with autoimmune diseases, is an immunomodulator that induces apoptosis of T and B cells. The efficacy of this steroidsparing agent has been demonstrated in patients with steroid dependent and refractory EGE disease. The usual dose for EGE patients is similar to that used in patients with IBD (22.5 mg/kg) [9, 60, 61] ; lower doses may not be effective [62] .
Montelukast sodium
Montelukast sodium, commonly used to treat asthma, is a selective leukotriene (LTD4) inhibitor with demonstrated efficacy for various eosinophilic disorders, including EGE. The majority of reports in the literature concerning its use in EGE (Table 3) [5, 9, 15, 21, 26, 6370] have shown significant clinical response in patients, either when the drug is used alone or in combination with steroids for induction and maintenance of remission in steroid dependent or refractory disease. The usual dose is 510 mg/d.
Oral cromolyn sodium
Oral cromolyn sodium is a mast cell stabilizer that blocks the release of immune mediators and the subsequent activation of eosinophils. While it has been shown to have significant efficacy in many of the reported cases of EGE, its effect was only modest in others, for unknown reasons (Table 4) [4, 52, 7177] . The usual dose is 200 mg tid or qid.
Ketotifene
Ketotifene is a 2 nd generation H1antihistamine agent that also modulates the release of mast cell mediators. Melamed et al [78] described 6 patients with EGE who responded clinically and histologically to ketotifen; however, Freeman et al [79] reported a single case in which the drug failed to maintain disease remission. This agent has also been proposed as an adjunct to steroids and montelukast for treating refractory EGE [5] . The usual dose is 12 mg twice daily.
Biologic agents
Biologic agents have also been reported in some case treat H. pylorirelated ulcers, is also known to have immunomodulatory effect, whereby its actions cause inhibition of T cell proliferation and induction of eosinophil apoptosis; these mechanistic actions in the immune system have led to clarithromycin being applied as maintenance therapy for patients with steroid dependent EGE who are in remission [47] .
Dietary therapy
Many dietary strategies have been proposed for manage ment of EGE based on results from food allergy tests. In general, when a limited number of food allergens is detected, patients should be maintained on a "targeted elimination diet" (TED). When many or no allergens are identified, the more aggressive "empiric elimination diet" or "elemental diet" can be used. Lucendo et al [48] investigated dietary treatment efficacy in EGE through a systematic review and found significant improvement in most cases, especially in those who undertook the elemental diet, which induced clinical remission in > 75% of cases. However, the validity of such a high efficacy rate was questionable since no confirmation of histologic response was available for the majority of cases included in the review. On the other hand, the authors noted that dietary measures were predominantly considered in the setting of mucosal disease, which is well known to be associated with food allergy, while the efficacy in muscular and serosal types, which show weaker linkage to food allergy [4] , was only rarely reported. In addition, patients' adherence and tolerability to such strategies remain an important drawback, especially when empiric elimination or elemental diets are used.
Thus, we suggest the TED for all EGE patients ( Figure  2 ) who show few food allergens upon testing. The overall data in the literature is insufficient to recommend empiric and total elimination diets in routine management; how ever, an elemental diet can be used initially as adjunct treatment for severe cases.
Prednisone
Prednisone remains the mainstay for induction of remission of EGE. While most of the case series reported have shown a response rate to prednisone (up to 90%) [3, 49] , the most recent reports showed remarkably lower values (only 50%) [7] . This steroid acts by inducing eosinophil apoptosis and inhibiting chemotaxis. The recommended initial dose of 0.5 to 1 mg/kg usually induces remission within a 2 wk period, with the most dramatic response occurring in patients with the serosal type [50] . Thereafter, tapering dosage over a 6 to 8 wk period is recommended. Reevaluation of the EGE diagnosis (and type) must be considered in cases of initial unresponsiveness [51] . Steroid dependent disease reportedly accounts for about 20% of cases [7] and, consequently, low doses of prednisone may be needed to maintain remission. Unfortunately, longterm steroid treatment predisposes some patients to serious side effects; in such cases, steroidsparing agents can be of benefit.
but without relieving symptoms, in 4 patients with EGE [80] ; unfortunately, another report associated its use studies of EGE. Mepolizumab (antiIL5) was reported to have improved tissue and peripheral eosinophilia, 
Intestinal layer Location Previous treatment Response
Russel et al [52] , 1994 1 Mucosal Ileum and cecum Intolerant to steroids Failure of cromolyn sodium and mesalazine Efficacy comparable to steroids over 5 mo Tan et al [53] , 2001 1 Full thickness with ascites Antrum Steroid dependent Remission (+) over 2 yr
Siewert et al [54] , 2006 1 Mucosal Duodenum to ileum None Response (+) Lombardi et al [55] , 2007 1 Mucosal + submucosal Ileum Relapse after stopping budesonide and cromolyn sodium Remission (+) on budesonide alone over 4 mo Elsing et al [56] , 2007 1 Muscular Jejunum Surgery + steroids for relapse Remission (+) over 3 mo Shahzad et al [57] , 2011 1 Mucosal Antrum + colon None Response (+) Busoni et al [58] , 2011 5 Mucosal Lower + upper GI tract Prednisone/methylprednisolone Remission (+) Lombardi et al [59] , 2011 1 Muscular Pyloric stenosis Methylprednisolone Remission (+) over 6 mo Müller et al [26] , 2014 1 Mucosal Duodenum + colon + ileum None 50% response (combined with 6-food elimination diet) Wong et al [15] , [66] , Copeland et al [9] , 2004 1 Mucosal Stomach Steroid refractory EGE (also receiving 6MP and 5ASA for UC)
Not effective
Friesen et al [67] , 2004 40 Mucosal Duodenum None Response (+) within 2 wk Quack et al [68] , 2005 1 Serosal Ileum Steroid dependent Remission (+) over 2 yr Urek et al [21] , Müller et al [26] , 2014 2 Mucosal (+/-serosal or muscular)
Stomach + small intestine 1 and 2 → Steroid dependent 1 → Remission (+) in combination with low-dose prednisone 2 → Remission (+) (off steroids) Wong et al [15] , such as reduction in peripheral eosinophilia [5] and improved radiologic aspects [88] . The choice of appropriate followup modality should always be individualized.
CONCLUsION
EGE is a chronic GI disease, having protean manifestations that mimic many other GI disorders. Its diagnosis requires a combination of clinical and pathologic criteria that are evaluated upon suspicious laboratory, radiologic and endoscopic findings. According to the disease severity at initial presentation, many therapeutic modalities can be applied, all of which have been reported in single and case series and have shown variable efficacy. A maintenance regimen is often needed, preferably based upon a safe steroidsparing drug. Further studies are needed to compare the efficacy and safety profiles of the various treatments available as well as to select predictors of relapses, which might guide decisionmaking for the kind and duration of maintenance therapy. with rebound hypereosinophilia [81] . Omalizumab (anti IgE) was reported to similarly result in a significant histologic response [82] but to be unlikely to efficiently treat EGE patients with a serum IgE level > 700 kIU/L [83] . Infliximab (antiTNF) was reported as highly effective for inducing remission in refractory EGE, but its use is limited by the development of resistance and secondary loss of response, both of which can be managed by switching to adalimumab [84] .
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Surgery
Surgery is indicated in cases of severe disease that are complicated by perforation, intussusception or intestinal occlusion. It has been reported that about 40% of EGE patients may need surgery during the course of their disease, and about half of those may experience persistent symptoms postoperatively [85] .
Other modalities
Other modalities include intravenous immunoglobulin and interferonalpha, both of which appear to be effective in treating severe refractory and steroid dependent cases [10, 65] . Suplatast tosilate, a TH2 cytokine inhibitor, can be beneficial as well [86] . Finally, fecal microbiota transplantation has also been reported to improve diarrhea in a patient with EGE, even before its application in combination with steroids [87] .
FOLLOW UP aND TREaTMENT ENDPOINTs
While most reported treatments of EGE aim to achieve clinical remission [48, 67] , histologic improvement remains the optimal way to assess a patient's response, even though it does not always correlate with clinical amelioration [79] . Biopsies can be obtained either endoscopically or under ultrasound guidance [27] . Other less invasive parameters may also be useful in monitoring of treatment response, Moots et al [71] , [72] , 1990 2 Mucosal Stomach + duodenum None Clinical and histologic response (+) after 4-5 mo Beishuizen et al [73] , 1993 2 Mucosal Upper gastrointestinal tract Steroids Prolonged response (+) Van Dellen et al [74] , 1994 1 Mucosal Stomach + duodenum Elemental diet (poorly tolerated)
Response (+)
Russel et al [52] , 1994 1 Mucosal Ileum + colon Steroid dependent None (failure to taper steroids) Pérez-Millán et al [75] , 1997 1 Serosal Duodenum None Response (+) over 6 mo Suzuki et al [76] , 2003 1 Mucosal Stomach + duodenum Targeted elimination diet (poorly tolerated)
Response (+) (in combination with ketotifene) Sheikh et al [77] , 
